Publications

Translational Research Publications

  • Fu J, Li S, Ma H, Yang J, Pagnotti G, Brown LM, Weiss SJ, Mapara MY, Lentzsch S. The Checkpoint Inhibitor PD-1H/VISTA Controls Osteoclast-Mediated Multiple Myeloma Bone Disease. Nature Communications. (2023) 14:4271.
  • Li S, Fu J, Walker CJ, Yang J, Butani D, Chakraborty R, Mamillapalli N, Mapara MY, Landesman Y, Lentzsch S. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Adv. (2023) 7(12):2926-2937.
  • Li S, Fu J, Yang J, Ma H, Bhutani D, Mapara MY,  Marcieau C, Lentzsch S. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma Blood. 2021 Apr 1;137(13):1754-1764.
  • Liu A, Li S, Donnenberg V, Fu J, Gollin SM, Ma H, Lu C, Stolz DB, Mapara MY, Monaghan SA, Lentzsch S. Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. Haematologica. 2018 Oct;103(10):1688-1697. 
  • Li S, Fu J, Wang H, Ma H, Xu X, Yang YG, Deng S, Mapara MY, Lentzsch S. IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Adv. 2018 Mar 13;2(5):492-504.
  • Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Wang J, Robinson S, Guo XE, Lund T, Normolle D, Mapara MY, Weiss SJ, Lentzsch S. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest. 2016 May 2;126(5):1759-72.
  • Li S, Fu J, Lu C, Mapara MY, Raza S, Hengst U, Lentzsch S. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma. Mol Cancer Ther. 2016 Apr;15(4):711-9.
  • Li S, Fu J, Ma H, Mapara MY, Lentzsch S. Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia. 2013 Jun;27(6):1407-11.
  • Feng R, Li S, Lu C, Andreas C, Stolz DB, Mapara MY, Lentzsch S. Targeting the microtubular network as a new antimyeloma strategy. Mol Cancer Ther. 2011 Oct;10(10):1886-96.
  • Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL, Lentzsch S. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011 May 12;117(19):5157-65.
  • Pal R, Janz M, Galson DL, Gries M, Li S, Jöhrens K, Anagnostopoulos I, Dörken B, Mapara MY, Borghesi L, Kardava L, Roodman GD, Milcarek C, Lentzsch S. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood. 2009 Oct 29;114(18):3890-8.

Clinical Research Publications

  • Edwards CV, Rao N, Bhutani D, Mapara MY, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A. Phase 1a/b Study of Monoclonal Antibody CAEL-101 (11-1F4) in Patients with AL Amyloidosis. Blood. 2021.
  • Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P,Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AD, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak W, Kwok F,  Shimazaki C, Kim JS, Crusoe E,  Ahmadi T, Tran N, Qin X, Vasey SV, Tromp B, Schecter JM, Weiss BM, huang SH, Vermeulen J, Merlini G, Comenzo RL for the ANDROMEDA Trial Investigators. Daratumumab-based Treatment for Immunoglobulin Light Chain Amyloidosis.  N Engl J Med. 2021 Jul 1;385(1):46-58.
  • Coltoff A, Bomback A, Shirazian S, Lentzsch S, Bhutani D. Treatment of monoclonal gammopathy associated C3 glomerulopathy with daratumumab-based therapy. Clin Lymphoma Myeloma Leuk. 2021 Apr 23:S2152-2650(21)00155-5.
  • Bhutani D, Pan S, Latif D, Goldsmith RL, Saith SE, Mapara MY, Chakraborty R, Lentzsch S , Maurer MS. Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis. Clin Lymphoma Myeloma Leuk. 2021 Apr 23:S2152-2650(21)00154-3.
  • Seymour EK, Khan HY, Li Y, Chaker M, Muqbil I, Aboukameel A, Ramchandren R, Houde C, Sterbis G, Yang J, Bhutani D, Pregja S, Reichel K, Huddlestun A, Neveux C, Corona K, Landesman Y, Shah J, Kauffman M, Shacham S, Mohammad RM, Azmi AS, Zonder JA. Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. Clin Cancer Res. 2021 Jun 15;27(12):3307-3316. PMID: 33785483.
  • Premkumar V, Pan S, Lentzsch S, Bhutani D. Use of Daratumumab in high risk Multiple Myeloma: A meta-analysis. eJHaem. 2020;1:267-271.
  • Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematology. 2020 Dec;7(12):e892-e901. PMID: 33242446
  • Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Annals of Hematology. 2020 May 7 [Epub ahead of print]. PMID: 32382772
  • Chakraborty R, Rybicki L, Nakashima MO, Dean RM, Faiman BM, Samaras CJ, Rosko N, Dysert H, Valent J, Anwer F. Characterization and prognostic impact of immunoparesis in relapsed multiple myeloma. British Journal of Haematology. 2020 Feb 28 [Epub ahead of print]. PMID: 32018328
  • Chakraborty R, Majhail N. Treatment and Disease-related Complications in Multiple Myeloma: Implications for Survivorship. American Journal of Hematology. 2020 Feb 22 [Epub ahead of print]. PMID: 32086970’
  • Basali D, Chakraborty R, Rybicki L, Rosko N, Reed J, Karam M, Schlueter K, Dysert H, Kalaycio M, Valent J. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. British Journal of Haematology. 2020 Feb 3 [Epub ahead of print]. PMID: 32012228
  •  Chakraborty R, Bin Riaz I, Malik SU, Marneni S, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer. 2020 Jan 8 [Epub ahead of print]. PMID: 31913498
  • Chakraborty R, Liu HD, Rybicki L, Tomer J, Khouri J, Dean RM, Faiman BM, Kalaycio M, Samaras BJ, Majhail NS, Valent J. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. American Journal of Hematology. 2019 Apr;94(4):439-445. PMID: 30663805
  • Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti JP, Ratanatharathorn V, Ayash L, Deol A, Alavi A, Revankar S, Chandrasekar P. Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. Bone Marrow Transplant. 2019 Jan;54(1):164-167.
  • Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018 Mar;32(3):712-718. PMID: 28848227
  • Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017 Aug;102(8):1439-1445. PMID: 28473618
  • Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biology of Blood and Marrow Transplantation. 2017 Apr;23(4):598-605. PMID: 28115277
  • Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal.  2016 Dec 16;6(12):e512. PMID: 27983726
  • Bhutani D, Gregory Dyson, Richard Manasa, Abhinav Deol, Voravit Ratanatharathorn, Lois Ayash, Muneer Abidi, Lawrence G. Lum, Uberti Joseph. Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64.